Quest Diagnostics Inc vs Quanta Services Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Quanta Services Inc trades at $705.94 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Quanta Services Inc for 62 Days on average.
| DGX | PWR | |
|---|---|---|
Market Cap | $25.48B | $103.03B |
Volume | 941,866 | 977,892 |
Sector | Health | Industrials |
52-Week High | $247.45 | $785.24 |
52-Week Low | $173.49 | $412.21 |
Typical Hold Time | 56 Days | 62 Days |
Enterprise Value | $31.23B | $109.13B |
Dividend Yield | 1.49% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Quanta Services (PWR) trades at $685.33, down 2.25% on the day, but maintains strong technical momentum with bullish moving averages and support at $684. The company demonstrates robust fundamentals with three consecutive quarterly earnings beats, 15.17% ROE, and accelerating revenue growth from $17.1B in 2022 to $28.5B in 2025. Analyst sentiment remains overwhelmingly positive with 27 buy ratings and a $802.08 consensus price target representing 17% upside potential.
PWR presents a compelling growth story with record $53B backlog and AI infrastructure tailwinds, though elevated valuation multiples (P/E 78.41) and execution risks on large projects warrant caution. The stock's proximity to its pivot point at $684 creates a critical technical level that could determine near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →